Editorial commentary: "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1205-1208

  Lee, Nelson ^a   Ison, Michael G ^b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE INHIBITOR;

CRITICAL ILLNESS; DISEASE DURATION; DISEASE SEVERITY; FATALITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SURVIVAL; SYMPTOM; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS SHEDDING;

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE;

EID: 84867514129     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis642     Document Type: Note

References (44)

1. World Health Organization. Influenza. Available at: http://www.who.int/ topics/influ enza/en/. Accessed 20 June 2012.
2. Dawood FS, Danielle Iuliano A, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study [ published online ahead of print 26 June 2012]. Lancet Infect Dis 2012; PMID: 22738893.
3. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012; 17(1 Pt B): 143-57. doi:10.3851/IMP2059.
4. McGeer A, Green KA, Plevneshi A, et al. Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75. (Pubitemid 351411840)
5. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510-5.
6. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009; 4:e6051.
7. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults - how are they different from seasonal influenza? J Infect Dis 2011; 203:1739-47.
8. Jain S, Kamimoto L, Bramley AM, et al. 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
9. Louie JK, Acosta M, Winter K, et al. California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302:1896-902.
10. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182:257-64.
11. Kumar A, Zarychanski R, Pinto R, et al. Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-9.
12. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-7.
13. Martin-Loeches I, Díaz E, Vidaur L, et al. H1N1 SEMICYUC/REIPI/CIBERESWorking group. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care 2011; 15:R286.
14. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-62.
15. Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 21 January 2011/60(RR01);1-24. Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr6001a1.htm. Accessed 20 June 2012.
16. Harper SA, Bradley JS, Englund JA, et al. Expert panel of the infectious diseases society of America. seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2009; 48:1003-32.
17. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis 2011; 204:1848-56.
18. Skarbinski J, Jain S, Bramley A, et al. 2009 Pandemic Influenza A H1N1 Virus Fall Hospitalizations Investigation Team. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States-September- October 2009. Clin Infect Dis 2011; 52(Suppl 1):S50-9.
19. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-204.
20. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512-24.
21. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a metaanalysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277-9.
22. Kumar D, Michaels MG, Morris MI, et al. American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-6.
23. Rodríguez A, Díaz E, Martín-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66:1140-9.
24. Farias JA, Fernández A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015-22.
25. Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011; 66:1150-5.
26. Morbidity and Mortality Weekly Report (MMWR). Maternal and infant outcomes among severely Ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1) - United States, April 2009-August 2010. 2011; 60:1193-1196.
27. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response in adults hospitalized for severe pandemic 2009 influenza A(H1N1) virus pneumonia. Antiviral Therapy 2011; 16:237-47.
28. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 2011; 17:1160-5. doi: 10.1111/j.1469-0691.2010.03399.x. 29.
29. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
30. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-5.
31. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-9.
32. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-25.
33. Viasus D, Paño-Pardo JR, Pachón J, et al. Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A (H1N1) virus infection. Chest 2011; 140:1025-32.
34. Yu H, Feng Z, Uyeki TM, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis 2011; 52:457-65.
35. Yang SG, Cao B, Liang LR, et al. National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012; 7:e29652.
36. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202:1154-60.
37. Aoki FY, Macleod MD, Paggiaro P, et al. IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9. (Pubitemid 36163836)
38. Leung YH, Lim WL, Wong MH, Chuang SK. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus. Epidemiol Infect 2012; 140:814-7.
39. Higuera Iglesias AL, Kudo K, Manabe T, et al. Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. PLoS One 2011; 6: e21838.
40. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in H5N1 avian influenza. J Infect Dis 2012 (in press).
41. Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother 2011; 66:959-63.
42. You JH, Chan ES, Leung MY, Ip M, Lee N. A cost-effectiveness analysis of 'test' versus 'treat' patients hospitalized with suspected influenza in Hong Kong. PLoS One 2012; 7: e33123.
43. Shorr AF, Owens RC Jr. Guidelines and quality for community-acquired pneumonia: measures from the joint commission and the centers for Medicare and Medicaid services. Am J Health Syst Pharm 2009; 66(12 Suppl 4):S2-7.
44. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for industry: influenza: developing drugs for treatment and/or prophylaxis. April 2011. Available at http://www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm091219.pdf. Accessed 20 June 2012.